<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162945">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667796</url>
  </required_header>
  <id_info>
    <org_study_id>JH067055</org_study_id>
    <nct_id>NCT01667796</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health</brief_title>
  <official_title>Pharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of oral vitamin D supplementation to determine if patients with
      Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum
      25-hydroxyvitamin D levels.  The investigators will also assess whether the immunologic or
      relevant gene expression response to oral vitamin D supplementation differs in patients with
      MS and healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change in mean serum level of 25-hydroxyvitamin D</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels and percentages of T and B cells</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression microarray</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Multiple Sclerosis, Relapsing-remitting</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Healthy or multiple sclerosis

          -  Aged 18 to 60

          -  Body mass index is between 18 kg/m2 and 30 kg/m2

          -  Screening 25-hydroxyvitamin D level ≤ 75 nmol/L (30 ng/mL)

          -  White race

          -  Non-Hispanic ethnicity

          -  Willing to use birth control during study

          -  Willing to not use tanning bed during study

        If subject has multiple sclerosis:

          -  Relapsing-remitting MS, as defined by McDonald 2005 criteria

          -  Screening Expanded Disability Status Scale score ≤ 3.0

          -  Using no medication for MS, or taking Copaxone, (glatiramer acetate), interferons, or
             natalizumab

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Taking multivitamin &amp; unwilling to remain off it during study

          -  Taking cod liver oil &amp; unwilling to remain off it during study

          -  On a fat-restricted diet

          -  History of renal disease or nephrolithiasis (kidney stones)

          -  History of liver disease

          -  Taking thiazide diuretics

          -  History of hyperthyroidism

          -  History of infection with Mycobacterium species

          -  History of sarcoidosis

          -  History of cancer

          -  History of cardiac disease

          -  History of HIV

          -  History of gastrointestinal disorder

          -  Taking medications that interfere with gastrointestinal absorption

          -  Cigarette smoker in past month

          -  Use of illicit drugs in past month

          -  Use of steroids in past month

          -  History of hypercalcemia, and screening serum calcium ≤ 10 mg/dL (UCSF) or ≤ 10.7
             mg/dL (Johns Hopkins)

          -  History of hypercalciuria

          -  Evidence of anemia (Hgb &lt;11.0 g/dL)

          -  History of other serious medical conditions

          -  Taking medications that involve the P450 system or may interact with vitamin D
             (digoxin, diltiazem, verapamil, cimetidine, heparin, or low-molecular weight heparin)

          -  Other concerns about safety from the perspective of the treating physician

        If subject has MS:

        -History of major heat sensitivity (leading to sun-avoidant behaviors)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen M Mowry, MD, MCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>August 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Ellen M. Mowry</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Healthy controls</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Vitamin D</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
